Synopsis
Since his first novel was published in 1985, Richard Powers has assembled a body of work whose intellectual breadth and imaginative energy bears comparison with that of any writer working today. Intersections: Essays on Richard Powers pays tribute to that achievement by collecting seventeen essays--written by leading literary critics, philosophers, and a novelist--each of which offers important insights into Powers's narrative craft and the intellectual grids that underlie his work. Powers's novels are distinguished by both their multiple narrative forms and their sophisticated synthesis of diverse fields of knowledge; to attempt to adequately address this range, the contributors to this volume mix their study of Powers's narrative innovations with eclectic interdisciplinary perspectives, which range from photography and systems theory, to ecocriticism and neuroscience. The volume concludes with an essay by Powers himself, that explores his philosophy of the novel.
"synopsis" may belong to another edition of this title.
About the Authors
Stephen J. Burn is associate professor of modern and contemporary literature at Northern Michigan University--Marquette. He is the author of "Jonathan Franzen at the End of Postmodernism; Intersections: Essays on Richard Powers;" and "David Foster Wallace's "Infinite Jest": A Reader's Guide."
Peter Dempsey is Senior Lecturer in English at the University of Sunderland, UK. He has published on contemporary American and Irish literature.
From the Back Cover
Since his first novel was published in 1985, Richard Powers has assembled a body of work whose intellectual breadth and imaginative energy bears comparison with that of any writer working today. Intersections: Essays on Richard Powers pays tribute to that achievement by collecting seventeen essays—written by leading literary critics, philosophers, and a novelist—each of which offers important insights into Powers’s narrative craft and the intellectual grids that underlie his work. Powers’s novels are distinguished by both their multiple narrative forms and their sophisticated synthesis of diverse fields of knowledge; to attempt to adequately address this range, the contributors to this volume mix their study of Powers’s narrative innovations with eclectic interdisciplinary perspectives, which range from photography and systems theory, to ecocriticism and neuroscience. The volume concludes with an essay by Powers himself, that explores his philosophy of the novel.
Contributors include Jon Adams, Sven Birkerts, Stephen J. Burn, Anca Cristofovici, David Cowart, Daniel C. Dennett, Joseph Dewey, Charles B. Harris, Scott Hermanson, Jenell Johnson, Bruno Latour, Barry Lewis, Paul Maliszewski, Richard Powers, Carter Scholz, Trey Strecker, Joseph Tabbi, Patti White.
9781586033552 The idea of specific, targeted therapy is not a new one, and the treatment of breast cancer provides the oldest example of such a targeted therapy. More than 100 years ago, Beatson demonstrated that estrogen deprivation (by oophorectomy) caused regression of breast cancer. With the understanding of the mechanism of estrogen and estrogen receptor function, drugs that inhibit receptor activation or prevent the production of estrogen have been developed. Today, these hormonal strategies play a central role in the treatment of the majority of patients with breast cancer. This publication is devoted to therapies that take advantage of molecular targets relevant to breast cancer – so called novel molecular therapies. The chapters are meant to be a sampling of the different approaches being taken to improve upon the current treatment of breast cancer. It presents a sampling of both old and new molecularly targeted therapies that are being developed. They represent the beginning of an exciting new era in cancer treatment. However, each new, targeted therapy will need to be validated in preclinical and clinical testing. Furthermore, while the expression of a specific protein or activity of a particular pathway provides an indication of which specific therapy to use, it does not guarantee that therapy targeted to that pathway will be effective. Thus, a thorough understanding of the pathways served by the target and additional information about the molecular phenotype of each tumor will be necessary to truly select those tumors that are most likely to respond to molecularly targeted therapies."About this title" may belong to another edition of this title.